AEMD Company Profile and Key Details

AEMD has shown mixed momentum, gaining 4.14% over the past week and -63.0% over the past quarter, though year-to-date performance is down -67.79%. Short-term trend indicators are bullishly aligned (SMA20 -11.27%, SMA50 -30.81%, SMA200 -81.66%). The stock’s 14-day RSI is 38.89 (weak momentum), while the ATR of 0.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.72% below its high and over 13.52% above its low. Average 10-day trading volume of 38.55 thousand shares is below the 3-month average of 60.02 thousand, indicating normal recent market interest.

Aethlon Medical, Inc. generated EPS of -$53.44 over the past year. Five-year average earnings growth is 43.53%. The latest quarter delivered EPS of -$3.74. The next quarter is forecast at -$2.60. Next year's EPS is expected at -$5.78. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $1.50. The high target offers 152.71% upside. The low target suggests -45.85% downside. The mean target is $4.80. This offers 73.29% upside. Aethlon Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 120.0%. The prior quarter beat by 25.0%. Over the last six quarters, Apple has recorded several small beats. These include -22.73% in August 14, 2024.

Aethlon Medical, Inc. has 971.87 thousand shares outstanding. The public float is 756.92 thousand shares, elevated short interest at 1.65% of float. This equals 12.51 thousand shares. The short ratio is 0.05 days. Institutional investors hold 4.94% of the float. Insiders own 1.9%. BROENNIMAN EDWARD G holds 282.17 thousand shares, BARRY FRANKLYN S JR has 106.59 thousand shares and Shah Chetan has 16.64 thousand shares.

Aethlon Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.11. This means the shares are trading below this model’s fair value.

Aethlon Medical, Inc. (NASDAQ:AEMD) closed at $2.77 USD, gaining $0.08 (2.97%) from the previous close of $2.69. The stock is currently mid-range between its 52-week high and low $2.44 and $76.00. With a market capitalization of about $2.11 million, Aethlon Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.64). Key stats such as the average daily volume over the past year has been around 119.74 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Aethlon Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO James Frakes, the company employs approximately 14 people and listed since March 04, 1999. Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.

Aethlon Medical, Inc. (NASDAQ:AEMD) shares are down -67.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aethlon Medical, Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $5.43, suggesting 96.03% upside. Our AI forecast model points to short-term weakness (-25.27% over two weeks), a medium-term fall (-96.75% over three months), and a longer-term loss (-68.95% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Aethlon Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.27%, with price expected at $2.07 by January 13, 2026, within a range of $1.61 to $2.50 3-Month Outlook: Projected fall of -96.75%, reaching $0.09 by March 30, 2026, with a range of $0.00 to $0.70. 1-Year Outlook: Projected loss of -68.95%, with price at $0.86 by December 30, 2026, within a range of $0.00 to $1.79.

Aethlon Medical, Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.18 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also below market averages.